Key Points
- Dongfang Liu sold 150,000 shares on December 1st at $7.82 for $1,173,000 and now directly holds 18,000 shares, an 89.29% decrease in his position.
- Including multiple November transactions, Liu has disposed of roughly $1.55 million of NUVB stock in recent sessions.
- Nuvation Bio beat Q results on revenue and slightly on EPS (reported -$0.16 vs. -$0.17 est.) but remains unprofitable; analysts’ consensus is a “Moderate Buy” with an average price target of $9.67.
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Dongfang Liu sold 150,000 shares of the firm's stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the transaction, the insider directly owned 18,000 shares of the company's stock, valued at $140,760. This represents a 89.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Dongfang Liu also recently made the following trade(s):
- On Wednesday, November 26th, Dongfang Liu sold 10,000 shares of Nuvation Bio stock. The stock was sold at an average price of $8.00, for a total value of $80,000.00.
- On Wednesday, November 19th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The shares were sold at an average price of $5.10, for a total value of $76,500.00.
- On Wednesday, November 19th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The shares were sold at an average price of $5.10, for a total value of $76,500.00.
- On Monday, November 17th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.76, for a total value of $71,400.00.
- On Monday, November 17th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.76, for a total value of $71,400.00.
Nuvation Bio Price Performance
NUVB stock opened at $8.35 on Thursday. The business's 50-day moving average is $5.01 and its two-hundred day moving average is $3.38. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. The firm has a market capitalization of $2.86 billion, a P/E ratio of -13.04 and a beta of 1.58. Nuvation Bio Inc. has a 1 year low of $1.54 and a 1 year high of $8.39.
Nuvation Bio (NYSE:NUVB - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%. The firm had revenue of $13.12 million for the quarter, compared to analyst estimates of $7.48 million. Analysts anticipate that Nuvation Bio Inc. will post -0.36 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in NUVB. Armistice Capital LLC boosted its holdings in shares of Nuvation Bio by 359.2% in the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company's stock valued at $8,495,000 after acquiring an additional 1,796,000 shares during the period. Millennium Management LLC boosted its stake in Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock worth $6,642,000 after purchasing an additional 1,298,131 shares during the period. Two Sigma Investments LP grew its position in Nuvation Bio by 95.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company's stock worth $8,797,000 after purchasing an additional 1,162,837 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Nuvation Bio in the third quarter valued at about $3,535,000. Finally, Natixis acquired a new stake in shares of Nuvation Bio during the second quarter worth about $1,766,000. Institutional investors and hedge funds own 61.67% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. Jefferies Financial Group started coverage on shares of Nuvation Bio in a research note on Tuesday, September 30th. They set a "buy" rating and a $10.00 target price for the company. Citizens Jmp upped their price objective on Nuvation Bio from $8.00 to $10.00 and gave the stock a "market outperform" rating in a research report on Thursday, November 20th. Citigroup reissued a "market outperform" rating on shares of Nuvation Bio in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nuvation Bio in a report on Wednesday, October 8th. Finally, B. Riley initiated coverage on shares of Nuvation Bio in a report on Wednesday, November 19th. They set a "buy" rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $9.67.
Get Our Latest Stock Report on Nuvation Bio
About Nuvation Bio
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
